Karolinska Development AB (publ) – Interim Report

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Karolinska Development AB (publ) – Interim Report January – June 2014

Torbjörn Bjerke, CEO, comments: “The ongoing efforts to partner Axelar’s drug candidate AXL1717 following the results presented in December last year from the Phase II study in non-small cell lung cancer has so far not met our expectations. The timeline and near-term commercial value of the company has therefore been adjusted.  As a consequence, the fair value of Axelar for the second quarter has therefore been written down, which has a significant effect on the interim fair value and net profit. Axelar remains active in finding a partner in order to move the project into the next clinical development steps.

During the second quarter, study results were reported in three of our portfolio companies’ drug development projects and another important clinical trial was initiated. 

Our portfolio company Aprea has developed substances that can that can restore normal function to the p53 protein, which plays a decisive role in cancer cells’ programmed death (apoptosis). In around half of all tumor cells, p53 has mutated and no longer functions normally. As a result, the cancer cells survive, leading to rapid tumor growth. In April, Aprea initiated a clinical trial with its substance APR-246 in patients with relapsed platinum sensitive ovarian cancer, a disease with a very poor prognosis. About 60% of all ovarian cancer patients have mutated p53 and the survival of these patients is lower than those with wild type p53.

Dilaforette took a step forward during the quarter in the development of an effective treatment for malaria. The results of an exploratory Phase I/II clinical trial with the drug candidate sevuparin found it to be safe and well tolerated. Due to problems recruiting a sufficient number of patients, however, the study was prematurely terminated. No statistical significance was found between sevuparin and the current standard treatment with regards to the appearance of mature parasitized red blood cells in circulation, which was the primary end-point of the study. The results however, indicate that sevuparin can produce better blood circulation and hence an improved clinical effect. Based on these findings, Dilaforette intend to approach relevant stakeholders in the malaria community with the aim to progress the program into the intended patient group, patients with severe malaria.   

Protein kinase inhibitors (PKI) are a class of drug that plays an important role in the treatment of various types of cancer and inflammation. Unfortunately, many PKIs have properties that make treatment unnecessarily complicated and in the worst cases can lead to a suboptimal effect or serious side-effects. Based on its proprietary HyNap drug delivery technology, XSpray Microparticles AB is developing a new formulation of the PKI nilotinib. The goal is to provide patients with a simpler and safer treatment. In May, the company presented study results clearly indicating that HyNap nilotinib has a better uptake in the body than the formulation of nilotinib used today. The results of the study also indicate that HyNap nilotinib uptake is not affected by food intake, one of the problems with current therapies. After these promising data, XSpray is evaluating strategies to fully capture the potential in the HyNap technology.

Premenstrual dysphoric disorder (PMDD) is a condition with a debilitating effect on the quality of life of about five percent of all women of child-bearing age. Umecrine Mood is the first company to develop substances that inhibit the metabolites believed to cause PMDD.  In June, it reported data from an exploratory clinical trial that show positive treatment effects among patients with severe symptoms. While the primary end point in the study was not reached, the substance was well tolerated and further analyses will now be conducted before a decision is made whether to continue development.

We are continuously evaluating and developing the portfolio through our clearly defined selection criteria with the aim to develop differentiated pharmaceutical and technology products based on prominent research. Our efforts continue to invest in our portfolio companies and their further efforts to address major medical needs and thereby build significant value for patients and shareholders.”

 

Summary of significant events during the second quarter 2014

  • Dosing initiated in Phase I/II clinical trial of APR-246 in patients with relapsed platinum sensitive ovarian cancer
  • XSpray announced positive Phase I data for HyNap™ nilotinib, demonstrating better bioavailability than for the current formulation of nilotinib
  • New Board Directors elected at the company’s Annual General Meeting
  • Dilaforette presented results from exploratory Phase I/II clinical trial in uncomplicated malaria, demonstrating that sevuparin is safe and well tolerated but due to premature termination of the trial, no evidence on effect could be concluded
  • Umecrine Mood reported preliminary data with UC1010 from exploratory Phase II study in premenstrual dysphoric disorder (PMDD), UC1010 was well tolerated but the trial did not reach its primary efficacy end point
  • Due to the partnering progress not reaching expectations the value of Axelar was written down

 

Summary of significant events after the second quarter 2014

There were no significant events after the reporting period.

 

Financial summary

    2014 2013 2014 2013
Investment entity Amounts in SEKm   Apr-Jun Apr-Jun (restated) Jan-Jun Jan-Jun (restated)
Condensed Income statement          
Change in fair value of portfolio companies   -177.3 49.8 -183.4 64.0
Net profit/loss   -189.5 35.8 -207.9 33.5
Condensed Balance sheet          
Cash and cash equivalents       29.8 156.1
Short-term investments       99.1 91.3
Total cash, cash equivalents and short-term investments       128.9 247.4
Share information          
Earnings per share, weighted average, before and after dilution (SEK)   -3.92 0.74 -4.31 0.69
Net asset value per share (SEK)       36.4 44.5
Equity per share (SEK)       36.3 44.4
Share price, last trading day in the reporting period (SEK)       22.0 27.2
Portfolio information          
Portfolio companies’ net cash¹       51.6 186.9
Investments in portfolio companies   33.8 158.8 49.3 174.4
Of which investments not affecting cash flow   6.7 0.0 6.7 3.8
Fair value of portfolio holdings       1,595.4 1,845.9
¹Portfolio companies’ net cash is comprised of the sum of cash, cash equivalents and short-term investments less external loans in portfolio companies regardless of Karolinska Development’s ownership interest

For further information, please contact: Torbjörn Bjerke, CEO, Karolinska Development AB Phone: +46 (0)72 744 41 23, e-mail: torbjorn.bjerke@karolinskadevelopment.com

Christian Tange, CFO, Karolinska Development AB Phone: +46 (0)73 712 14 30, e-mail: christian.tange@karolinskadevelopment.com

 

TO THE EDITORS

About Karolinska Development AB Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into differentiated products that can be partnered. The business model is to: SELECT the most commercially attractive medical innovations that can potentially satisfy unmet medical needs; DEVELOP innovations to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products. An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading universities, delivers a continuous flow of innovations. Today, the portfolio consists of 33 projects, of which 16 are in clinical development. For more information, please visit www.karolinskadevelopment.com.

Karolinska Development is listed on NASDAQ OMX. Karolinska Development may be required to disclose the information provided herein pursuant to the Securities Markets Act.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Envision and Tsinghua Propel Climate Innovation at COP31

Updated Category News Views 87

Collaborating for a Greener Future On the bustling stage of COP31 in Antalya, Turkey, Envision Energy and Tsinghua University teamed up with the Global Alliance of Universities on Climate (GAUC) to showcase a bold agenda. Their focus transcends mere dialogue, pushing for actionable climate solutions anchored in technological innovation, academic synergy, and the dynamism...

Continue Reading
A Teen's Opera Encounter Inspires Decades of Passion

Updated Category News Views 0

Unraveling a Lifelong Opera Obsession Back in the dog-eared days of 1970, a teenager waltzed into the Metropolitan Opera and stumbled onto a passion that'd pulse alongside him for over half a century. Now, David E. Lapin rolls out his personal chronicle, 'A Sound Obsession: Fifty-Five Years of Opera at the Met.' Folks, we’re diving into a cultural tapestry that’s...

Continue Reading
Jones Soda Expands into Nutrition with UCAN Deal

Updated Category News Views 145

Well, Jones Soda Co. (CSE: JSDA) is stirring the pot with its recent move to acquire the UCAN functional nutrition assets. Popped the news on November 12, 2026, and it turns out they've shelled out a cool $700,000 in cash and taken on $500,000 in liabilities for the privilege. This isn't some casual shuffle of dollars and cents—this one's a strategic gambit aimed at...

Continue Reading
Ampace Focuses on Battery Safety Standards at RE+ 2026

Updated Category News Views 146

Battery Safety Takes Center Stage No mystery here: the safety of our beloved lithium-ion batteries is crucial, especially as AI data centers sprout like weeds. At RE+ 2026, Ampace is putting its chips on the table by spotlighting this hot topic. Dr. Drew Feng, their Chief Safety Officer, is set to reveal the big guns: findings from the PU100 large-scale fire test. Mark...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 279

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Daqo New Energy Faces Key Investor Meeting in December

Updated Category News Views 88

Spotlight on December's Agenda for Daqo Shareholders Who'd have thought we'd be looking at another year end with the same burning energy interests? Daqo New Energy Corp. (NYSE: DQ) is setting up for its annual general meeting (AGM) dated December 10, 2026. Mark your calendars, because these gatherings can be more than just straightforward affairs; sometimes they reveal...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 86

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Bacterial Breakthrough in Cancer Therapy: Game Changer?

Updated Category News Views 7

Blurring Lines Between Bugs and Biotech Well, wouldn't you know it, the eggheads over at Jeonbuk National University in South Korea are at it again, pushing the boundaries of what these little bacterial buggers can do. This time, they’ve had a crack at cancer therapy, using engineered Salmonella to pack a double punch against breast cancer in mice. Now, if that ain't...

Continue Reading
SwitchBot's Hub 4: A Step Toward a Connected Future

Updated Category News Views 37

Turning a House Into a Smart Home Haven Out of Tokyo and onto the world stage, SwitchBot's got something new cooking that might just shake up the smart home scene. They've launched the Hub 4, a gadget that's like the Swiss Army knife of home control. For those who like things simple, this is a one-hub-to-rule-them-all kind of deal. 101,000 Reasons to Notice Now, they...

Continue Reading
Nord Anglia Schools Shine with 13 Tes Awards Nominations

Updated Category News Views 87

Nord Anglia's Moment of Glory at Tes Awards You think you know the big players in the educational game? Well, guess again. Nord Anglia's come out swinging with a whopping 13 finalist nominations at the 2026 Tes Awards for International Schools. It ain't easy making waves in the education sector, but these folks are showing they've got what it takes to turn heads, not just...

Continue Reading

Top 5 Most Recently Viewed Articles

Piper Sandler Welcomes John Kerins to Healthcare Team

Updated Category News Views 218

Piper Sandler Expands Healthcare Investment Banking Expertise Piper Sandler Companies (NYSE: PIPR), a prominent name in investment banking, is excited to announce a significant addition to their healthcare investment banking team with the hiring of John Kerins as a managing director. This strategic move reflects the firm’s commitment to strengthening its presence in the...

Continue Reading
Exploring North America's Last Mile Delivery Growth and Trends

Updated Category News Views 346

Exploring North America's Last Mile Delivery Growth and Trends The last mile delivery market in North America is poised for significant growth over the next few years. Experts estimate that this market could expand by USD 14.9 billion between 2025 and 2029. This impressive growth is being driven primarily by the increasing demand for business-to-consumer (B2C) e-commerce....

Continue Reading
Mastercard Marks 20 Years on NYSE with Digital Shift

Updated Category News Views 39

A Landmark Moment at the NYSE for Mastercard Ah, another day in the whirlwind of the stock universe, where birthdays are celebrated with the finesse of boardroom discussions. Mastercard (NYSE: MA) is taking a well-deserved spotlight as it cheers two decades since it hit the seal of the New York Stock Exchange. Back on May 26th, it wasn't just business as usual. Nope, they...

Continue Reading
Insights into the Expanding Network of China-Europe Freight Trains

Updated Category News Views 236

The Rise of China-Europe Freight Trains Recently, a significant milestone was reached when the 110,000th China-Europe freight train departed from Jiaozhou Station, fully loaded with various goods such as electronic displays and household appliances. This service has now transported goods worth over USD 450 billion, showcasing its crucial role in global trade. The Journey...

Continue Reading
Netflix Investors Encouraged to Report Losses Amid Investigation

Updated Category News Views 217

Investigation Focus on Netflix, Inc. (NASDAQ: NFLX) Recently, significant scrutiny has emerged surrounding Netflix, Inc. (NASDAQ: NFLX), as Edelson Lechtzin LLP, a prominent national law firm known for handling class action lawsuits, initiates an investigation into potential violations of federal securities laws. This inquiry seeks to determine whether Netflix and certain...

Continue Reading